PF-Atlas › Clinical Trials › NCT06843239
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation
Tibulizumab · Phase 2
Registry ID
NCT06843239
Phase
Phase 2
Status
Recruiting
Drug / intervention
Tibulizumab
Sponsor
Zura Bio Inc
Start
2025-02-06
Enrollment
80
Locations
60
About this trial
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06843239 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.